Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.

Samankaltaisia teoksia

• Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
  Tekijä: Croucher, P, et al.
  Julkaistu: (2002)
• Zoledronic acid prevents the development of myeloma bone disease and increases survival
  Tekijä: Shipman, C, et al.
  Julkaistu: (2002)
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
  Tekijä: Croucher, P, et al.
  Julkaistu: (2001)
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
  Tekijä: Croucher, P, et al.
  Julkaistu: (2001)
• Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
  Tekijä: Croucher, P, et al.
  Julkaistu: (2003)